GSK CEO: Drug Discovery, AI in Pharma, and Changing Company Culture

Episode Summary

Executive Summary: Emma Walmsley outlines GSK’s strategy to drive growth through heavy R&D investment, prioritization of vaccines and specialty medicines, and adoption of AI/tech to improve drug discovery, trials, and access. She highlights major near-term approvals, cancer and hepatitis breakthroughs, vaccine leadership, AMR preparedness, and the need to balance innovation, affordability, trust, and global health impact.

Main Topics: GSK’s R&D reset and pipeline: Walmsley explains how she reallocated capital toward vaccines and specialty medicines, expanded external partnerships, and built a pipeline of 14 scaled medicines/vaccines expected this decade. AI and technology in drug discovery: She argues AI/GenAI will transform target selection, molecule design, manufacturing, clinical trials, and patient identification, improving speed, cost, and success rates. Vaccines and preventive health: Walmsley frames vaccines as one of healthcare’s best returns on investment, discusses GSK’s shingles and RSV vaccines, and emphasizes older-adult vaccination and pandemic readiness. Cancer, hepatitis B, and new modalities: She highlights antibody-drug conjugates for multiple myeloma and oligonucleotides for hepatitis B as examples of new platform technologies with major patient impact. Access, pricing, and social responsibility: She rejects an either/or between pricing and access, stressing that scale, profitability, and broad access are all necessary to fund innovation and improve global health equity. Culture, leadership, and organizational change: Walmsley says GSK’s cultural overhaul—greater accountability, clearer ownership, talent reset, and performance focus—was essential to restoring agility and growth. Public health resilience and antimicrobial resistance: She discusses lessons from COVID, supply chain security, vaccine hesitancy, and AMR as a slow-moving pandemic requiring continued antibiotic innovation.

Key Arguments: GSK must continually reinvent itself because the pharmaceutical patent model forces replacement of the portfolio every decade. AI and genomics can materially improve R&D productivity by reducing time, cost, and failure rates across the discovery-to-trial pathway. Precision medicine and biomarkers allow smaller, better-targeted clinical trials that can increase success probability and enable functional cures. Vaccines deliver exceptional preventive value, especially for infectious disease and older adults, and can reduce downstream hospital costs. Innovation and access are complementary, not contradictory: pricing must cover failure and fund R&D, while access programs and tiered pricing expand reach. Culture is a leadership responsibility, not an HR exercise; performance improvement required clearer accountability, talent renewal, and consistent messaging. Pharma’s future growth will increasingly depend on oncology, infectious disease, respiratory, HIV, and new platform technologies such as ADCs, oligonucleotides, and mRNA. The industry must prepare for pandemics and AMR simultaneously, with supply chain resilience and sustained antibiotic development.

Data Points: GSK ownership by Norwegian Sovereign Wealth Fund: 1.7% - Nikola Tangen states the fund’s stake in GSK at the start of the conversation. Stake value: $1.3 billion - Value of the Norwegian Sovereign Wealth Fund’s ownership in GSK. Expected new approvals this year: 5 - Walmsley says GSK expects five new drug/vaccine approvals this year. Planned scale medicines and vaccines: 14 - She describes a cohort of 14 potential scale launches this decade. Potential sales per launch: >£2 billion - Each of the 14 medicines/vaccines could exceed this sales level. Multiple myeloma new diagnoses annually: 180,000 - Used to illustrate the unmet need addressed by ADCs. Hepatitis B global burden: 250 million people - Walmsley cites the scale of the disease and the promise of a functional cure. COPD/asthma population: 300 million people - Context for GSK’s respiratory drug Trelegy. HIV injection frequency today: 6 times a year - Current long-acting HIV regimen dosing cadence. HIV injection frequency target: 4 times a year - Future dosing goal for long-acting HIV solutions. Shingles vaccine efficacy: 90% protection for at least 11 years - She describes GSK’s shingles vaccine as a multi-billion asset. RSV vaccine efficacy/hospitalization coverage: Over 90% efficacy on populations representing 90% of hospitalization - Walmsley cites the RSV vaccine’s impact. R&D failure rate: 90% - She notes this industry-wide failure rate as a core economic challenge. Time to discover/develop a drug: About a decade - Used to explain the long development cycle and capital needs. Share of world’s data related to healthcare: One third - She argues healthcare is a major opportunity for AI and technology. People without access to needed healthcare: 2 billion - Walmsley frames access as a global responsibility. World’s children vaccinated by GSK programs: 40% - She says GSK’s global programs vaccinate a large share of children. Donated doses for neglected tropical disease: 440 million - She cites donations for lymphatic filariasis in Africa. US hospital spending on vaccine-preventable diseases: $9 billion per year - Used to argue prevention has economic value. UK lives expectancy gap: 12 years - Example showing access and health inequality within London. Medicines centrally approved in Europe (2022) unavailable in Norway: 40% of 278 - Used to argue access issues also affect rich countries. AMR projected deaths by 2050: 38 million - Her estimate of the “slow pandemic” of antimicrobial resistance. GSK investment in Fleming/Imperial AMR work: $40 million - She mentions support for UK-led antibiotic research. Manufacturing and vaccine/medicine investment in the US: $800 million - Recent announced investment in regional supply-chain resilience. 2031 outlook upgrade: Second upgrade - She says GSK upgraded its outlook again at the start of the year. Added outlook value over four years: $7 billion - Part of GSK’s growth reset under Walmsley. Sales growth this decade: $17 billion - She says GSK will grow by this amount this decade. Company size reduction: From about 100,000 to 70,000 employees - Walmsley references organizational change and simplification.

Pivotal Quotes: "There is no better return on investment than vaccine technology." — Emma Walmsley: She explains why vaccines are central to GSK’s strategy and to preventive healthcare. "Culture is the, it's not an HR issue. It's not something we write on the wall. It is literally the job of the leadership of the company." — Emma Walmsley: On how she drove GSK’s internal transformation and accountability shift. "It is not an either or, it is an and, but we have to do a better job of communicating also about the business model and the value that our industry brings." — Emma Walmsley: She addresses the tension between drug pricing, access, and the economics of innovation.

Implications: GSK is betting that AI-enabled R&D, precision trials, and new platform drugs will accelerate breakthroughs while expanding access. The broader industry faces pressure to prove value, rebuild trust, and prepare for future pandemics and AMR.